Disease Domain | Count |
---|---|
Infectious Diseases | 5 |
Top 5 Drug Type | Count |
---|---|
Unknown | 1 |
Prophylactic vaccine | 1 |
Recombinant protein | 1 |
Vaccine | 1 |
Monoclonal antibody | 1 |
Top 5 Target | Count |
---|---|
toxB(Toxin B) | 1 |
PfCSP(Plasmodium falciparum circumsporozoite protein) | 1 |
Target |
Mechanism toxB inhibitors |
Active Org. Lumen Bioscience, Inc.Startup |
Originator Org. Lumen Bioscience, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. Lumen Bioscience, Inc.Startup |
Originator Org. Lumen Bioscience, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. Lumen Bioscience, Inc.Startup [+1] |
Originator Org. Lumen Bioscience, Inc.Startup [+1] |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date19 Aug 2024 |
Sponsor / Collaborator Lumen Bioscience, Inc.Startup |
Start Date01 May 2024 |
Sponsor / Collaborator Lumen Bioscience, Inc.Startup |
Start Date06 Oct 2023 |
Sponsor / Collaborator Lumen Bioscience, Inc.Startup |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
LMN-201 ( toxB ) | Clostridium difficile infection More | Phase 3 Clinical |
LMN-101 | Campylobacter Infections More | Phase 2 |
LMN-301 | COVID-19 More | Phase 1 |
Spirulina-based malaria vaccine ( PfCSP ) | Malaria More | Preclinical |
Recombinant oral malaria vaccine (Lumen Bioscience) | Malaria More | Preclinical |